Advertisement

AI Bias Analysis

4 models · Takes ~15 seconds

CNBC

Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC

EconomyDaily Composite

Analysts see the biotech company as a prime takeover target and several pharma giants have been rumored as potential buyers.

C

Source

CNBC

Read full article at CNBC

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement